by Elana Gotkine In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Oct. 29 in the Annals of Internal Medicine, updated recommendations are presented for the management of migraine and tension-type headache (TTH). Noting that the 2020 U.S. Department of Veterans Affairs and U.S. Department...
Tag: <span>Migraine</span>
Post
New First-Line Therapies for Migraine
I’m Dr Neil Skolnik and today we are going to talk about the position statement from the American Headache Society (AHS) “Calcitonin Gene-Related Peptide-Targeting Therapies Are a First-Line Option for the Prevention of Migraine,” which is focused on calcitonin gene-related peptide (CGRP)–targeting therapies. This update is of critical importance because about three fourths of people with migraine get their...
Post
New First-Line Therapies for Migraine
Medscape Family Medicine > Clinical Guidelines for Primary CareCOMMENTARY Neil Skolnik, MD DISCLOSURES | August 07, 2024 This transcript has been edited for clarity. I’m Dr Neil Skolnik and today we are going to talk about the position statement from the American Headache Society (AHS) “Calcitonin Gene-Related Peptide-Targeting Therapies Are a First-Line Option for the...
Post
Why Don’t Migraine Patients Seek Treatment?
Medscape Medical News > Conference News Pauline Anderson June 19, 2024 SAN DIEGO, California — Nearly one in three patients with migraine is reluctant to seek medical help and many blame health care providers, results of a recent survey showed. Participants cited concerns that their complaints would be dismissed, a belief that health care providers...
Post
Proton Pump Inhibitors Tied to Migraine, Other Severe Headache Types
Medscape Medical News Eve Bender May 03, 2024 Proton pump inhibitors (PPIs), which are used to control acid reflux, are associated with an increased risk for migraine and other severe headache types, new research showed. Using data from the National Health and Nutrition Examination Survey (NHANES) investigators conducted a cross-sectional analysis and found all types...
Post
Migraine pain caused by lack of lymphatic system drainage in brain, study suggests
JULY 11, 2024 by University of North Carolina at Chapel Hill School of Medicine Credit: Journal of Clinical Investigation (2024). DOI: 10.1172/JCI175616Migraine is a chronic and debilitating neurological condition affecting women 3 to 4 more times than men. Despite an estimated 1.1 billion people being impacted by the condition, the physiological underpinnings of migraine remain...
Post
Researchers identify unknown signaling pathway in the brain responsible for migraine with aura
by University of Copenhagen Credit: Pixabay/CC0 Public Domain A previously unknown mechanism by which proteins from the brain are carried to a particular group of sensory nerves causes migraine attacks, a new study shows. This may pave the way for new treatments for migraine and other types of headaches. The work appears in Science. More...
Post
New Guidance on CGRPs as First-Line Migraine Prevention: How/Will it Change Clinical Practice?
Eve Bender June 20, 2024 A position statement released by the American Headache Society (AHS) earlier this year recommended adding calcitonin gene-related peptide (CGRP)–targeting medications to the list of first-line therapies for migraine prevention. The guidance replaces recommendations published in 2021 that advised clinicians consider CGRP therapy only after patients fail at least two classes...
Post
No Link Between Habitual Caffeine Use and Migraine
Batya Swift Yasgur TOPLINE:Habitual consumption of caffeine is not associated with frequency, duration, or intensity of episodic migraines, a new study showed. Investigators said the findings suggest caffeine restrictions in migraineurs may not be necessary. METHODOLOGY:The secondary analysis of a prospective cohort study on sleep in adults with episodic migraine (with or without aura) included...
Post
CGRP in Migraine Prodrome Can Stop Headache, Reduce Severity
Sue Hughes BARCELONA — For the first time, new research shows that taking a specific class of migraine medication during the prodromal phase reduces the development and severity of the subsequent headache. In the randomized, placebo-controlled crossover PRODROME trial, treatment with ubrogepant (Ubrelvy) 100 mg, one of the new CGRP receptor antagonists, during the prodrome...